Showing results (541-550 of 554) with videos related to

Sort By:
Pageof 56
Research Involvement and Engagement|July 19, 2022
Standardised data on initiatives-STARDIT: Beta versionJack S Nunn, Thomas Shafee, Steven Chang, et al.
Aesthetic Surgery Journal. Open Forum|June 30, 2025
Botulinum Toxin: Surely, We Can Do Better? Optimizing Results Beyond On-Label Techniques and TeachingGreg J Goodman, Adrian Lim, Sarah Hart, et al.
Emerging Infectious Diseases|February 9, 2026
Multiplex PCR to Differentiate Monkeypox Virus CladesChristopher T Williams, Alessandra Romero-Ramirez, Adeleye Adesola Semiu, et al.
Frontiers in Immunology|August 15, 2022
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Frontiers in Immunology|January 27, 2023
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Nature Communications|June 23, 2019
Identification of HIV transmitting CD11c+ human epidermal dendritic cellsKirstie M Bertram, Rachel A Botting, Heeva Baharlou, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2021
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous AustraliansLuca Hensen, Thi H O Nguyen, Louise C Rowntree, et al.
EMBO Molecular Medicine|June 17, 2026
Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndromeMartin Killian, Suzanne K Shoffner-Beck, Timon Damelang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Ebiomedicine|December 6, 2021
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Thomas S Fulford, Huy Van, Nicholas A Gherardin, et al.
Pageof 56